Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology, Neurology, and Autoimmune Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ADAM10 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ADAM10 ECD-Fc Fusion Protein (Metalloprotease Domain Active) High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). Theoretical MW confirmed. |
View ADAM10 Products |
| Gene Delivery | ADAM10 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Preserves native membrane conformation. |
View ADAM10 Products |
| Benchmark Ab | Anti-ADAM10 Recombinant Antibody Sequence-defined positive control for binding and blocking assays. |
View ADAM10 Products |
| Validator | ADAM10 siRNA Set (3 unique sequences) For knockdown verification and assay specificity controls. |
View ADAM10 Products |
| Related Target: ADAM17 | ADAM17 (TACE) Subfamily counter-screening; closely related sheddase with overlapping substrate repertoire. |
View ADAM17 Products |
| Related Target: NOTCH1 | NOTCH1 Key ADAM10 substrate (S2 cleavage); essential for pathway validation. |
View NOTCH1 Products |
| Related Target: APP | Amyloid Precursor Protein (APP) Non-amyloidogenic α-secretase substrate; neurodegeneration axis validation. |
View APP Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse eval | Human/Mouse/Cyno ADAM10 ortholog ECD proteins available with >95% purity; Sequence Verified |
| Subfamily counter screening | ADAM homolog panel (ADAM8, ADAM9, ADAM12, ADAM15, ADAM17) strictly verified by mass spectrometry |
| Lack of Controls | Clinical Benchmark Antibodies (Research Grade) included |
| False Positives / Specificity | Validated siRNA included for knockdown specificity checks |
Live ADAM10 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ADAM10 therapeutics is intensifying, with the field shifting from broad-spectrum metalloprotease inhibitors toward highly selective biologics. Historically, non-selective small molecules failed due to severe dose-limiting toxicities (e.g., liver and skin toxicity from MMP inhibition). As first-generation antibody and ADC programs advance through preclinical validation, the next wave of R&D is targeting substrate-selective modulation and combination strategies in solid tumors and Alzheimer's disease. Current R&D focuses heavily on achieving selectivity over ADAM17 (TACE) to avoid dose-limiting toxicities associated with Notch pathway disruption in the gut.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Emerging Biotech / Academic Consortiums | Solid Tumors (EGFR ligand shedding), Immuno-Oncology | Blocking Assay (Need high-purity ECD-Fc with native metalloprotease domain folding) |
| ADC | Discovery-Stage Biotech | Oncology (ADAM10-overexpressing tumors) | Internalization Assay (Need full-length Lentivirus stable cell line for native conformation) |
| Small Molecule Inhibitor | Academia / Drug Discovery Platforms | Alzheimer's Disease, Oncology | Selectivity Assay (Need WT vs metalloprotease-dead mutant recombinant proteins) |
| Bispecific / Combination | Early-Stage Developers | Tumor Microenvironment Modulation | Ternary Complex Validation (Need cross-reactive ortholog panel) |
Molecular Differentiation & Assay Strategy
1. Affinity & Epitope Design
- Need: High-affinity binding to the metalloprotease (MP) or disintegrin domain for catalytic blocking or allosteric modulation.
- Assay: SPR/BLI using Human, Cyno, Mouse ADAM10 ortholog ECD-Fc proteins (TarMart: sequence-verified, >95% purity). Epitope binning with MP and disintegrin domain truncations.
2. Internalization Efficiency (for ADC)
- Need: Efficient endocytosis and lysosomal trafficking for payload release.
- Assay: Live-cell internalization using pHrodo-labeled antibodies or ADC mimics on ADAM10-overexpressing stable cell lines (TarMart: full-length ORF lentivirus).
3. Selectivity (vs. ADAM17 & MMPs)
- Need: >100-fold selectivity over ADAM17 to avoid TNF-α/IL-6R dysregulation and inflammation.
- Assay: Cross-reactivity panel with ADAM8, ADAM9, ADAM12, ADAM15, ADAM17 (TarMart: mass-spec verified homolog panel). Catalytic-dead mutant (E384A) for binding mode differentiation.
4. Safety Epitope (Substrate-Selective Modulation)
- Need: Preserve physiological Notch1 S2 cleavage while blocking pathological substrate shedding (e.g., AREG/TGF-α).
- Assay: Reporter cell lines for Notch1 vs. APP shedding (TarMart: NOTCH1 and APP lentivirus). siRNA knockdown for specificity baseline.
5. Stability & Formulation
- Need: High-concentration (>100 mg/mL) stability for subcutaneous injection.
- Assay: SEC-HPLC and DLS for aggregation propensity. TarMart high-purity ADAM10 ECD-Fc for antigen-antibody complex stability testing.